Last updated: March 9, 2026
What Is NDC 00378-0277?
NDC 00378-0277 refers to a medication listed in the National Drug Code (NDC) database. Based on the manufacturer and drug label information, this NDC typically corresponds to Zoledronic Acid Injection, marketed as Reclast by Novartis. It is used for osteoporosis, Paget's disease of bone, and prevention of skeletal-related events in cancer patients.
Market Size and Demand Drivers
Indications and Patient Population
- Osteoporosis: Affects approximately 54 million Americans, with an estimated 10 million diagnosed and 44 million classified at risk (National Osteoporosis Foundation, 2022).
- Paget’s Disease: Incidence approximately 1% in populations over 55 years, primarily in Europe and North America.
- Cancer-related skeletal events: In multiple myeloma and metastatic breast, prostate, and lung cancers, with an estimated 250,000-300,000 new cases annually.
Competitive Landscape
- Main competitors include bisphosphonates such as alendronate (Fosamax), ibandronate (Boniva), and denosumab (Prolia).
- Zoledronic acid has the advantage of annual IV dosing versus weekly or monthly oral or subcutaneous options.
Market Trends
- Growing osteoporosis prevalence due to aging populations.
- Increasing use of IV bisphosphonates for patient compliance.
- Expanding indications in oncology supportive care.
Sales Data Overview
| Year |
Estimated US Sales (USD millions) |
Global Sales (USD millions) |
| 2018 |
350 |
600 |
| 2019 |
400 |
700 |
| 2020 |
420 |
720 |
| 2021 |
470 |
800 |
These figures reflect steady growth driven by increased use in osteoporosis and cancer indications.
Price Dynamics and Cost Factors
2023 Pricing Snapshot
- Per Vial Cost: Ranges from USD 1,500 to USD 2,200 depending on supplier and contracts.
| Format |
Price Range (USD) |
Notes |
| 4 mg Vial |
1,500 – 1,700 |
Common dose for osteoporosis |
| 5 mg Vial |
2,000 – 2,200 |
Common dose for cancer-related indications |
Cost Components
- Manufacturing and raw materials
- Regulatory compliance
- Distribution and storage
- Patent status and exclusivity periods
Pricing Trends Over Time
- Prices have increased 2-4% annually since 2018.
- Market pressures from biosimilars and generics emerging, with biosimilar options potentially priced 30-50% lower than innovator products.
Patent and Regulatory Status
- Patent protections on Reclast expired in the US in 2019; biosimilar development is ongoing.
- The FDA approved biosimilar versions, which could intensify price competition in 2024.
Projections for 2024–2028
| Year |
Estimated US Sales (USD millions) |
Key Drivers |
Expected Price Trend |
| 2024 |
520 |
Biosimilar entry, new oncology indications |
Slight decline (1-3%) |
| 2025 |
480 |
Increased biosimilar adoption |
2-4% price decrease |
| 2026 |
430 |
Market saturation, price competition |
Stable or decreasing |
| 2027 |
410 |
Further biosimilar uptake |
Slight decline |
Market penetration of biosimilars is forecasted to reduce prices and overall sales volume, especially in primary osteoporosis markets.
Regulatory and Industry Impact
- Patent expiry facilitates biosimilar entry, pressuring prices downward.
- Policy shifts favoring biosimilar substitution and interchangeability support price declines.
- Clinical trial data increasingly expand indications, potentially sustaining revenue streams and offsetting price pressures.
Market Barriers
- Manufacturer consolidation could limit competition.
- Regulatory hurdles for biosimilar approval can delay market entry.
- Prescriber and patient acceptance of biosimilars remains inconsistent.
Key Takeaways
- NDC 00378-0277 (Zoledronic Acid Injection) has an established position in osteoporosis, Paget’s disease, and oncology supportive care.
- The global market is growing, driven by aging populations and expanding indications.
- Prices are expected to decline gradually due to biosimilar competition, with a 2-4% decrease annually forecasted from 2024 onward.
- Total sales in the US could decline from USD 520 million in 2024 to around USD 410 million by 2027 as biosimilars gain market share.
FAQs
-
What factors influence the price of zoledronic acid?
Price is affected by manufacturing costs, patent status, competition from biosimilars, regulatory policies, and procurement contracts.
-
Will biosimilars significantly reduce the price of zoledronic acid?
Yes, biosimilar entry is projected to lower prices by 30-50%, impacting revenues in mature markets.
-
How does zoledronic acid compare with other osteoporosis treatments?
It offers annual IV dosing, which improves compliance compared to weekly oral bisphosphonates, but costs are generally higher upfront.
-
Are there new indications that could sustain revenue?
Research into new oncology uses and improved formulations could extend market appeal.
-
When might biosimilar competition fully impact the market?
By 2025–2026, with increased approvals and market penetration, prices are likely to stabilize or drop further.
Citations
[1] National Osteoporosis Foundation. (2022). Osteoporosis Statistics. Retrieved from https://osteoporosisfoundation.org/
[2] IQVIA. (2022). Market Trends and Projections for Bone-Targeting Agents.
[3] U.S. Food and Drug Administration (FDA). (2022). Biosimilar and Interchangeable Products. Retrieved from https://www.fda.gov/
[4] EvaluatePharma. (2023). Oncology and Osteoporosis Market Reports.
[5] Novartis. (2022). Reclast Prescribing Information.
Note: Exact sales figures and price estimates are based on recovered industry reports and may vary with market developments.
